Boryung Pharm - Asset Resilience Ratio
Boryung Pharm (003850) has an Asset Resilience Ratio of 8.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Boryung Pharm (003850) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how Boryung Pharm's Asset Resilience Ratio has changed over time. See Boryung Pharm (003850) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Boryung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Boryung Pharm stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩116.42 Billion | 8.59% |
| Total Liquid Assets | ₩116.42 Billion | 8.59% |
Asset Resilience Insights
- Limited Liquidity: Boryung Pharm maintains only 8.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Boryung Pharm Industry Peers by Asset Resilience Ratio
Compare Boryung Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Boryung Pharm (2009–2024)
The table below shows the annual Asset Resilience Ratio data for Boryung Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.40% | ₩4.67 Billion ≈ $3.17 Million |
₩1.16 Trillion ≈ $788.89 Million |
+0.01pp |
| 2023-12-31 | 0.39% | ₩3.59 Billion ≈ $2.44 Million |
₩915.51 Billion ≈ $620.43 Million |
+0.19pp |
| 2022-12-31 | 0.21% | ₩1.84 Billion ≈ $1.25 Million |
₩892.39 Billion ≈ $604.76 Million |
-5.92pp |
| 2021-12-31 | 6.12% | ₩50.73 Billion ≈ $34.38 Million |
₩828.64 Billion ≈ $561.56 Million |
-3.94pp |
| 2020-12-31 | 10.06% | ₩65.21 Billion ≈ $44.19 Million |
₩647.99 Billion ≈ $439.14 Million |
+10.02pp |
| 2019-12-31 | 0.04% | ₩213.73 Million ≈ $144.85K |
₩507.63 Billion ≈ $344.01 Million |
-0.01pp |
| 2018-12-31 | 0.05% | ₩213.18 Million ≈ $144.47K |
₩450.02 Billion ≈ $304.97 Million |
-0.01pp |
| 2017-12-31 | 0.05% | ₩214.70 Million ≈ $145.50K |
₩402.52 Billion ≈ $272.78 Million |
-0.05pp |
| 2016-12-31 | 0.10% | ₩410.37 Million ≈ $278.10K |
₩397.90 Billion ≈ $269.65 Million |
+0.10pp |
| 2012-12-31 | 0.00% | ₩3.82 Million ≈ $2.59K |
₩273.01 Billion ≈ $185.01 Million |
0.00pp |
| 2011-12-31 | 0.00% | ₩3.76 Million ≈ $2.55K |
₩262.39 Billion ≈ $177.82 Million |
+0.00pp |
| 2010-12-31 | 0.00% | ₩2.29 Million ≈ $1.55K |
₩245.86 Billion ≈ $166.61 Million |
0.00pp |
| 2009-12-31 | 0.00% | ₩2.29 Million ≈ $1.55K |
₩176.79 Billion ≈ $119.80 Million |
-- |
About Boryung Pharm
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, So… Read more